Alkermes aripiprazole lauroxil data looks good, says Leerink Leerink says the data Alkermes presented from its Phase III trial of aripiprazole lauroxil for treatment of schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting looks good. The firm expects FDA approval of AL in Q3 of 2015 following a 12-month regulatory review. It maintains an Outperform rating on the stock with a $66 price target.
News For ALKS From The Last 14 Days
Check below for free stories on ALKS the last two weeks.